MOVYMIA® (teriparatide)

MOVYMIA® the teriparatide biosimilar from Thornton & Ross, STADA. MOVYMIA® is indicated for adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.1

API - Prescribing Information can be found here

Why treat osteoporosis?

In the UK, more than 3 million people are estimated to have osteoporosis. Reduced bone density is the major risk factor for fragility fracture, but other factors also increase the risk.2 Increasing age in both sexes and menopause in women leads to increased bone loss, and therefore the prevalence of osteoporosis increases markedly with age - for example, in women it increases from 2% at 50 years of age to >25% at 80 years of age.2 Approximately 549,000 fragility fractures occur annually. Such fractures cause severe pain, disability, and reduction in quality of life.3

19.6% increase in the number of fragility fractures is predicted by 20303

Ageing of the UK population is predicted to give rise to a 19.6% increase in the number of fragility fractures by 2030 if changes are not made to current practice.3

MOVYMIA® (teriparatide)



https://stadaspecialtybiosimilars.co.uk/wp-content/uploads/2023/09/img8.jpg

Indications

Movymia® is approved in the UK for the treatment of:1,*

  • Osteoporosis in post-menopausal adult women at increased risk of fracture
  • Osteoporosis in adult men at increased risk of fracture
  • Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk of fracture

Dose

The recommended dose for Movymia® is 20 μg/80 μl, self-administered once daily via a subcutaneous injection in the thigh or abdomen1

https://stadaspecialtybiosimilars.co.uk/wp-content/uploads/2023/09/img9.jpg

Minimal Waste

Cartridge lasts for 28 days1
Pen lasts for full treatment period1

The safety profile of Movymia® is equivalent to the reference product4,a

MOVYMIA® (teriparatide) HCP and Patient Support:

We understand that information to support you and your patients on their treatment journey is essential to their treatment success. We have developed a range of resources to support you and your patient through the injection process and help your patients understand more about their treatment. 

Clinical Resource:

Man Looking Mobile

Lets stay connected!

Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?

References

1. Movymia 20 micrograms/80 microliters solution for injection Summary of Product Characteristics (SmPC), Available at: https://www.medicines.org.uk/emc/product/10780 (accessed November 2022). 2. UK consensus guideline on the management of patients at low, high, and very high risk of osteoporotic fracture. Available at: https://pcwhf.co.uk/resources/uk-consensus-guideline-on-the-management-of-patients-at-low-high-and-very-high-risk-of-osteoporotic-fracture/ (accessed November 2022). 3. National Osteoporosis Guideline Group UK (NOGG), clinical guideline for the prevention and treatment of osteoporosis. Updated September 2021. Available at: https://www.nogg.org.uk/full-guideline (accessed November 2022). 4. STADA. Movymia® European Public Assessment Report, 2017. Available at: https://www.ema.europa.eu/en/documents/assessment-report/movymia-epar-public-assessment-report_en.pdf (accessed November 2022). 5. DM+D available at:https://services.nhsbsa.nhs.uk/dmd-browser/amp/view/153616 and at https://services.nhsbsa.nhs.uk/dmd-browser/amp/view/153615 (accessed November 2022).

* As “increased risk of fracture” is not defined in the Movymia® Summary of Product Characteristics, it needs to be determined by the treating physician on a case-by-case basis and/or based on local guidelines. † Less waste by volume – one Movymia® cartridge per month versus one Forsteo® pre-filled syringe per month.

a. Based on data from clinical trials with teriparatide; b. ≥1% difference in frequency from placebo; c. Based on a randomised, double-blind, single-dose (20 μg/80 μL subcutaneous injection), fixed-dose, 2-way crossover comparative study of Movymia® and the reference product in 54 healthy, adult pre-menopausal females; d. Assessed in a comparative 4-week repeat-dose toxicity study in rats; e. Assessed in a large clinical trial with women receiving teriparatide.

Information

For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MULT-122b | Date of Preparation: August 2023